Kura Oncology Inc (KURA) Stock Analysis
Verdict: HOLD
Ziftomenib commercialization creates significant upside, but a $70.7M annual cash burn creates dilution risk within 24 months.
Investment score: 62/100
Analysis as of
Is Kura Oncology Inc stock worth reviewing? AI model thesis
The model score of 62/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 60/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 75/100 (weight 15%)
- Earnings Quality: 45/100 (weight 15%)
- Insider Sentiment: 70/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 65/100 (weight 15%)
Kura Oncology Inc opportunities and risks
What speaks for KURA
- Ziftomenib Commercial and Partnering Expansion
What speaks against KURA
- Accelerated Cash Burn and Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KURA | n/a | 13.4x | n/a | 94.7% | -384.3% | -11.3% |
| JBIO | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.8% |
| SVRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.1% |
| GLUE | n/a | 37.8x | n/a | 92.9% | -560.9% | -6.6% |
| CRVS | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.3% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.3% |
Frequently asked questions about Kura Oncology Inc (KURA)
Is KURA stock a good investment?
The cached TradeMates AI model rates Kura Oncology Inc as HOLD with an investment score of 62/100. The model score of 62/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is KURA stock a buy?
The TradeMates model verdict for KURA is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.